Blood Coagulation Testing Market Information: By Product (Clinical Laboratory, Automated), Application (Bleeding Disorders, Von Willebrand Disease), Test Type (Testing Kits), and End Users (Academic Institutions, Hospitals) - Global Forecast till 2023

Market Scenario

Blood coagulation or clotting is the process by which blood changes from liquid to gel, thus, forming clots. These clots result in cessation of bleeding. However, the process of coagulation is hindered in the people suffering from liver disease, thrombophilia, and hemophilia. Various blood coagulation testing procedures are used for diagnosing these diseases, which provide the status of the hemostatic functioning of the patient. Haemostatic involves a coordinated series of interactions between platelets and numerous blood clotting proteins. With increasing prevalence of hemostatic diseases, the demand for blood coagulation testing has increased. To analyses the treatment efficiency against hemostatic diseases, the blood clotting testing is required.

The liver plays an important role in the normal functioning of hemostasis, which helps in preventing bleeding and undue activation of coagulation. According to the Centers for Disease Control and Prevention (CDC), in 2015, around 3.9 million adults were diagnosed with liver disease, which is about 1.6% of adult population of the U.S.

According to a study conducted by the Global Burden of Disease Liver Cancer Collaboration, in 2015, around 854,000 new incidents of liver cancer were found and 810,000 deaths occurred owing to liver cancer globally. Furthermore, it is the sixth most common-incident cancer globally and the fourth most common cause of cancer death.

Moreover, advancing technology in blood coagulation testing is adding fuel to the growth of the market. Furthermore, increasing prevalence of liver disease, thrombophilia, and hemophilia also drives the market growth. However, availability of expensive treatment and poor reimbursement policies in the developing regions of the world are some of the factors, which may hamper the market growth during the forecast period.

The global blood coagulation testing market is expected to grow at a CAGR of 6.5 % during the forecast period 2017-2023.

Intended Audience

- Medical Diagnostic Kit Manufacturers
- Pharmaceutical Industries
- Research and Development (R&D) Companies
- Medical Research Laboratories
- Academic Medical Institutes and Universities

Figure: Global Blood Coagulation Testing Market, By Region Market Share, 2016 (%)
The global blood coagulation market is segmented on the basis of product, application, test type, and end user.

On the basis of the product, the market is segmented into clinical laboratory, automated testing, and semi-automated testing.

On the basis of application, the market is segmented into congenital bleeding disorders, acquired bleeding disorders, Von Willebrand disease, and hemophilia.

On the basis of test type, the market is segmented into various testing kits and others. Furthermore, testing kits are segmented into prothrombin time (PT), activated clotting time, D dimer, and fibrinogen (FIB).

On the basis of the end user, the market is segmented into academic institutions, hospitals, and diagnostic laboratories.

**Regional Analysis**

The Americas dominate the global blood coagulation testing market owing to increasing patient with liver disease, von Willebrand disease (vWF), and hemophilia. Furthermore, well-developed technology, high health care spending, increasing government support for research & development, and the concentration of major companies have fuelled the growth of the market in this region.

Europe holds the second position in the global blood coagulation testing market owing to the government support for research & development and availability of funds for research. This is expected to continue to drive the European market over the forecast period. For instance, countries like Germany and France are increasing investment in the healthcare domain. According to a study conducted by Global Burden of Disease Liver Cancer Collaboration, in 2017, Western Europe ranked third in the liver cancer cases and fourth in liver cancer death.

The Asia Pacific is the fastest growing blood coagulation testing market owing to the presence of rapidly developing healthcare technology, a huge patient population, and high healthcare expenditure. Moreover, increasing demand for new treatment methods in countries like India and South Korea is likely to emerge as the fastest growing market across the globe. Furthermore, increasing demand for quality devices in the healthcare is projected to lead to the use of advanced equipment, which, in turn, is likely to increase the growth of the blood coagulation testing Market in the region.

On the other hand, in the Middle East and Africa, blood disorders have become a huge problem due to limited screening, ignorance of diseases, and poor access to treatment.

**Key Players**

Some of the major players for the global blood coagulation market are F. Hoffmann-La Roche Ltd. (Europe), Alere Inc. (U.S.), Siemens Healthcare Private Limited (Europe), Accriva Diagnostics (U.S.A.), CoaguSense, Inc. (U.S.), HomoSonics LLC. (U.S.), iLine Microsystems. (Europe),
Instrumentation Laboratory (U.S.), Sienco, Inc. (U.S.), SenGenix Inc. (U.S.), Bio/Data Corporation (U.S.)

Research Methodology

Sources: Annual reports, Press release, White paper, and Company presentation

Contents:

Table of Content
1. Report Prologue
2. Market Introduction
   2.1 Definition
   2.2 Scope of the Study
      2.2.1 Research Objective
      2.2.2 Assumptions
      2.2.3 Limitations
3. Research Methodology
   3.1 Introduction
   3.2 Primary Research
   3.3 Secondary research
   3.4 Market Size Estimation
4. Market Dynamics
   4.1 Drivers
   4.2 Restraints
   4.3 Opportunities
   4.4 Challenges
   4.5 Macroeconomic Indicators
   4.6 Technology Trends & Assessment
5. Market Factor Analysis
   5.1 Porters Five Forces Analysis
      5.1.1 Bargaining Power of Suppliers
      5.1.2 Bargaining Power of Buyers
      5.1.3 Threat of New Entrants
      5.1.4 Threat of Substitutes
      5.1.5 Intensity of Rivalry
   5.2 Value Chain Analysis
   5.3 Investment Feasibility Analysis
   5.4 Pricing Analysis
   6.1 Introduction
   6.2 Clinical Laboratory
      6.2.1 Market Estimates & Forecast, 2017-2023
   6.3 Automated
      6.3.1 Market Estimates & Forecast, 2017-2023
6.4 Semi-Automated Testing
6.4.1 Market Estimates & Forecast, 2017-2023

7.1 Introduction
7.2 Bleeding Disorders
7.2.1 Market Estimates & Forecast, 2017-2023
7.3 Acquired Bleeding Disorders
7.3.1 Market Estimates & Forecast, 2017-2023
7.4 Von Willebrand Disease
7.4.1 Market Estimates & Forecast, 2017-2023
7.5 Hemophilia
7.5.1 Market Estimates & Forecast, 2017-2023

8. Global Blood Coagulation Testing Market, by Test Type
8.1 Introduction
8.2 Testing Kits
8.2.1 Market Estimates & Forecast, 2017-2023
8.3 Others
8.3.1 Market Estimates & Forecast, 2017-2023

9.1 Introduction
9.2 Academic Institutions
9.2.1 Market Estimates & Forecast, 2017-2023
9.3 Hospitals
9.3.1 Market Estimates & Forecast, 2017-2023
9.4 Diagnostic Laboratories
9.4.1 Market Estimates & Forecast, 2017-2023

10. Global Blood Coagulation Testing Market, by Region
10.1 Introduction
10.2 Americas
10.2.1 North America
10.2.1.1 U.S.
10.2.1.2 Canada
10.2.2 South America
10.3 Europe
10.3.1 Western Europe
10.3.1.1 Germany
10.3.1.2 France
10.3.1.3 U.K.
10.3.1.4 Italy
10.3.1.5 Spain
10.3.1.6 Rest of Western Europe
10.3.2 Eastern Europe
10.4 Asia Pacific
10.4.1 Japan
10.4.2 China
10.4.3 India
10.4.4 Australia
10.4.5 Republic of Korea
10.4.6 Rest of Asia Pacific
10.5 The Middle East & Africa
10.5.1 United Arab Emirates
10.5.2 Saudi Arabia
10.5.3 Oman
10.5.4 Kuwait
10.5.5 Qatar
10.5.6 Rest of the Middle East & Africa

11 Company Landscape
11.1 Introduction
11.2 Market Share Analysis
11.3 Key Development & Strategies
11.3.1 Key Developments

12 Company Profiles
12.1 F. Hoffmann-La Roche Ltd
12.1.1 Company Overview
12.1.2 Product Overview
12.1.3 Financials
12.1.4 SWOT Analysis
12.2 Alere Inc.
12.2.1 Company Overview
12.2.2 Product Overview
12.2.3 Financial Overview
12.2.4 Key Developments
12.2.5 SWOT Analysis
12.3 Siemens Healthcare
12.3.1 Company Overview
12.3.2 Product Overview
12.3.3 Financial Overview
12.3.4 Key Development
12.3.5 SWOT Analysis
12.4 Accriva Diagnostics
12.4.1 Company Overview